AbbVie stock weekly forecast: Holds gains as buyers stay in control

AbbVie stock weekly forecast: Holds gains as buyers stay in control
AbbVie slips 0.76% over the week

Shares of AbbVie Inc. (ABBV) are trading near $293 as buyers maintain control in a quiet week. The setup heading into next week focuses on whether this steady tone can hold, with key support and resistance levels likely to shape the action.

ABBV price prediction
24H 0.33%
$286.89
48H 0.05%
$286.11
7D -0.6%
$284.24
1M 3.59%
$296.23
3M 12.01%
$320.31
6M 5.01%
$300.29
12M 26.97%
$363.09
Current price: $285.96 -6.9000 2.36%
Closed 11/18
Daily range 284.91 Arrow from to Icon 292.55
Weekly range 291.00 Arrow from to Icon 301.20
Loading...

Highlights

  • Shares of AbbVie closed at $292.86, slightly below last week, but remain above key long-term averages.
  • Technical indicators show a mixed short-term outlook with MACD on a buy signal and Stochastic RSI in oversold territory.
  • AbbVie stock is expected to fluctuate between $287.85 and $297.86 over the next five days, with a 64% probability of an increase.

Neuroscience growth and new partnerships boost sentiment and sales outlook

AbbVie's neuroscience franchise delivered 19.5% operational sales growth in the third quarter of 2026, driving the company to raise its 2026 segment sales outlook to $13 billion, according to Yahoo Finance. During the week, ABBV also expanded its pipeline by entering new AI-driven drug discovery collaborations, including extending its partnership with Brise Pharmaceuticals for migraine programs and launching a collaboration with Iambic for pipeline development. Consensus sales estimates for the current quarter point to 11% year-over-year revenue growth, as reported by Yahoo Finance.

AbbVie Inc. asset chart
AbbVie Inc. price dynamics. Source: TradingView.

Mixed technical signals emerge as MACD rallies and RSI nears exhaustion

On the daily chart, AbbVie is showing a firm trend with a sustained move lower, as confirmed by a volatility reading of 3.86%. Momentum signals present a mixed picture: MACD remains in strong buy territory at 5.56, but the Stochastic RSI is in the oversold zone, suggesting possible selling exhaustion and a risk of near-term rebound. Immediate support is seen at $290.45, with additional backing from the Ichimoku Kijun at $288.27, while resistance is defined by the recent high at $301. This sets the stage for potential volatility as the stock reacts to technical levels in the days ahead.

Range-bound bias expected unless support or resistance breaks next week

Over the next five trading days, AbbVie is expected to trade between $287.85 and $297.86, with a 64% probability of an increase and a 36% probability of a decrease. The base case favors further price action developing within this range as the trend consolidates. A break above resistance at $301 would open a path for additional gains, while a decisive move below the $290.45 support level could expose downside risk toward the lower end of the forecast range.

Viktoras Karapetjanc, expert at Traders Union, sees AbbVie shares demonstrating robust performance near $293 this week, with buyers maintaining a clear edge. He highlights that the company's impressive growth in its neuroscience franchise and the expansion of AI-driven drug discovery partnerships are strengthening the long-term outlook. Strong technical momentum, especially with MACD in firm buy territory and oversold signals from the Stochastic RSI, support the potential for a rebound from current levels. As long as immediate support at $290.45 and the Ichimoku Kijun at $288.27 hold, the trend remains constructive into the coming week, with upside potential toward resistance at $301 and beyond if positive sentiment persists. "With momentum and fundamentals aligned, I see high odds for further growth in AbbVie shares as the bullish structure remains intact."

Earlier, analysts noted that AbbVie's technical setup suggested a sustained uptrend with the potential for further gains, while cautioning about possible inflection points. The current analysis adds new context with a shift to consolidation and emerging volatility, highlighting $301 as a key level that could trigger renewed upside momentum if decisively breached.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.